Non-Small Cell Lung Cancer - Epidemiology Insights to 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 40
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Non-Small Cell Lung Cancer -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Non-Small Cell Lung Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Non-Small Cell Lung Cancer. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Non-Small Cell Lung Cancer. The report contains the targeted patient populations and the forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Key Coverage and Benefits

  • The Report includes the prevalent population and how will it change over the next eight years.

  • Coverage of key Non-Small Cell Lung Cancer sub-populations and its prevalent or incident cases

  • Prevalent or incident cases segmented by age and sex.

  • The key differences in epidemiology patterns across the seven market segments.

Reasons to buy

  • Developing business strategies by understanding the trends shaping and driving the global Non-Small Cell Lung Cancer market.

  • Identifying prevalent patient populations as well as risk factors in the global Non-Small Cell Lung Cancer market will help to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the best opportunities for Non-Small Cell Lung Cancer therapeutics in each of the markets covered.

Non-Small Cell Lung Cancer - Epidemiology Insights to 2025

Table of Contents

1. Report Introduction

2. Snapshot of Total Prevalent or Incident cases by 7 MM

3. Executive Summary
Key Findings

4. Non Small Cell Lung Cancer Overview
Non Small Cell Lung Cancer Definition
Pathophysiology
Symptoms
Etiology

5. Risk Factors Associated with Non Small Cell Lung Cancer

6. Disease Burden & Unmet Need in the Market

7. Epidemiology and Patient Populations
Key Findings
Key Sources used and Forecast Methodology
Prevalent Cases and Incident Cases-2015-2025
Prevalent & Incident Cases by Category-2015-2025
Age-Specific Prevalent/ Incident Cases of Non Small Cell Lung Cancer
Sex-Specific Prevalent/Incident Cases of Non Small Cell Lung Cancer
Disease Type Specific Prevalent/Incident Cases of Non Small Cell Lung Cancer

8.Prevalent & Incident Cases by 7 MM-2015-2025
Non Small Cell Lung Cancer Epidemiology of United States-2025
Non Small Cell Lung Cancer Epidemiology of United Kingdom-2025
Non Small Cell Lung Cancer Epidemiology of Germany-2025
Non Small Cell Lung Cancer Epidemiology of France-2025
Non Small Cell Lung Cancer Epidemiology of Spain-2025
Non Small Cell Lung Cancer Epidemiology of Italy-2025
Non Small Cell Lung Cancer Epidemiology of Japan-2025

9. Key Takeaways

10. Appendix

11.Report Methodology

12. Consulting Services

13. Disclaimer

14. About Us

List of Tables

Table 1: Clinical subtypes of Indication
Table 2: Risk Factors
Table 3: Prevalence cases (%) Region wise
Table 4: Sources used for forecasting the data
Table 5: Non-Small Cell Lung Cancer Global Epidemiology, (2015-2025)
Table 6: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), US (2015-2025)
Table 7: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), US (2015-2025)
Table 8: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, US (2015-2025)
Table 9: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), United Kingdom (2015-2025)
Table 10: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), United Kingdom (2015-2025)
Table 11: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, United Kingdom (2015-2025)
Table 12: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Germany (2015-2025)
Table 13: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Germany (2015-2025)
Table 14: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, Germany (2015-2025)
Table 15: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), France (2015-2025)
Table 16: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), France (2015-2025)
Table 17: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, France (2015-2025)
Table 18: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Italy (2015-2025)
Table 19: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Italy (2015-2025)
Table 20: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, Italy (2015-2025)
Table 21: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Spain (2015-2025)
Table 22: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Spain (2015-2025)
Table 23: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, Spain (2015-2025)
Table 24: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Japan (2015-2025)
Table 25: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Japan (2015-2025)
Table 26: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population, Japan (2015-2025)

List of Figures

Figure 1: Prevalence cases (%) Region wise
Figure 2: Sources used for forecasting the data
Figure 3: Non-Small Cell Lung Cancer Global Epidemiology, (2015-2025)
Figure 4: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), US (2015-2025)
Figure 5: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), US (2015-2025)
Figure 6: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,US (2015-2025)
Figure 7: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), United Kingdom (2015-2025)
Figure 8: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), United Kingdom (2015-2025)
Figure 9: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,United Kingdom (2015-2025)
Figure 10: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Germany (2015-2025)
Figure 11: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Germany (2015-2025)
Figure 12: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,Germany (2015-2025)
Figure 13: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), France (2015-2025)
Figure 14: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), France (2015-2025)
Figure 15: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,France (2015-2025)
Figure 16: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Italy (2015-2025)
Figure 17: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Italy (2015-2025)
Figure 18: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,Italy (2015-2025)
Figure 19: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Spain (2015-2025)
Figure 20: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Spain (2015-2025)
Figure 21: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,Spain (2015-2025)
Figure 22: Prevalent Cases of Non-Small Cell Lung Cancer (Ages =XX Years), Japan (2015-2025)
Figure 23: Prevalent Cases of Non-Small Cell Lung Cancer By Sex (Males & Females), Japan (2015-2025)
Figure 24: Prevalent Cases By Non-Small Cell Lung Cancer Sub-population,Japan (2015-2025)
  • Global Cancer Immunotherapy Market Analysis & Forecast to 2022 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors
    Published: 23-Oct-2017        Price: US 4900 Onwards        Pages: 370
    Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022. This report describes the evolution of such a huge market in 20 chapte......
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 254
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-......
  • Peritoneal Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 876
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal......
  • Rhabdomyosarcoma - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 226
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2017, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness.......
  • Fallopian Tube Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 875
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2017, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopaus......
  • Global Kaposi Sarcoma Market Size, Status and Forecast 2022
    Published: 06-Oct-2017        Price: US 3300 Onwards        Pages: 98
    This report studies the global Kaposi Sarcoma market, analyzes and researches the Kaposi Sarcoma development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck - Pfizer - Johnson & Johnson - GlaxoSmithKline - Bristol-Myers Squibb - Eli Lilly Market segment by Regions/Countries, this report covers - United States - EU - ......
  • Oligodendroglioma - Pipeline Review, H2 2017
    Published: 30-Sep-2017        Price: US 2000 Onwards        Pages: 148
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor......
  • Esophageal Cancer - Pipeline Review, H2 2017
    Published: 30-Sep-2017        Price: US 2000 Onwards        Pages: 591
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.......
  • Global Cancer Supportive Care Market 2017-2021
    Published: 21-Sep-2017        Price: US 3500 Onwards        Pages: 96
    Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others. The analysts forecast global cancer supportive ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs